Plain-English translation of NCT07298395 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing a new medication called for adults with moderate to severe atopic dermatitis (a chronic skin condition that causes itching, redness, and inflammation). The study will involve about 60 participants who will take either the medication or a placebo once daily for 12 weeks to see if the treatment safely reduces skin symptoms and improves quality of life.
Many people with moderate to severe atopic dermatitis don't respond well enough to current topical treatments like creams and steroids. This medication is being developed to offer a new option for those who need better relief from their symptoms.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll visit the clinic every 2 to 4 weeks for 12 weeks, during which you'll take either the new medication or a placebo once daily at home. You'll also keep a simple diary of your symptoms and medication use, have your skin assessed by the study team, and undergo blood tests or other checks to monitor your safety. After the 12-week treatment period ends, you'll return for a final visit around week 16.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States